Cargando…

Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis

Technological advances in passive digital phenotyping present the opportunity to quantify neurological diseases using new approaches that may complement clinical assessments. Here, we studied multiple sclerosis (MS) as a model neurological disease for investigating physiometric and environmental sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Chitnis, Tanuja, Glanz, Bonnie I., Gonzalez, Cindy, Healy, Brian C., Saraceno, Taylor J., Sattarnezhad, Neda, Diaz-Cruz, Camilo, Polgar-Turcsanyi, Mariann, Tummala, Subhash, Bakshi, Rohit, Bajaj, Vikram S., Ben-Shimol, David, Bikhchandani, Nikhil, Blocker, Alexander W., Burkart, Joshua, Cendrillon, Raphael, Cusack, Michael P., Demiralp, Emre, Jooste, Sarel Kobus, Kharbouch, Alaa, Lee, Amy A., Lehár, Joseph, Liu, Manway, Mahadevan, Swaminathan, Murphy, Mark, Norton, Linda C., Parlikar, Tushar A., Pathak, Anupam, Shoeb, Ali, Soderberg, Erin, Stephens, Philip, Stoertz, Aaron H., Thng, Florence, Tumkur, Kashyap, Wang, Hongsheng, Rhodes, Jane, Rudick, Richard A., Ransohoff, Richard M., Phillips, Glenn A., Bruzik, Effie, Marks, William J., Weiner, Howard L., Snyder, Thomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906296/
https://www.ncbi.nlm.nih.gov/pubmed/31840094
http://dx.doi.org/10.1038/s41746-019-0197-7
_version_ 1783478316378882048
author Chitnis, Tanuja
Glanz, Bonnie I.
Gonzalez, Cindy
Healy, Brian C.
Saraceno, Taylor J.
Sattarnezhad, Neda
Diaz-Cruz, Camilo
Polgar-Turcsanyi, Mariann
Tummala, Subhash
Bakshi, Rohit
Bajaj, Vikram S.
Ben-Shimol, David
Bikhchandani, Nikhil
Blocker, Alexander W.
Burkart, Joshua
Cendrillon, Raphael
Cusack, Michael P.
Demiralp, Emre
Jooste, Sarel Kobus
Kharbouch, Alaa
Lee, Amy A.
Lehár, Joseph
Liu, Manway
Mahadevan, Swaminathan
Murphy, Mark
Norton, Linda C.
Parlikar, Tushar A.
Pathak, Anupam
Shoeb, Ali
Soderberg, Erin
Stephens, Philip
Stoertz, Aaron H.
Thng, Florence
Tumkur, Kashyap
Wang, Hongsheng
Rhodes, Jane
Rudick, Richard A.
Ransohoff, Richard M.
Phillips, Glenn A.
Bruzik, Effie
Marks, William J.
Weiner, Howard L.
Snyder, Thomas M.
author_facet Chitnis, Tanuja
Glanz, Bonnie I.
Gonzalez, Cindy
Healy, Brian C.
Saraceno, Taylor J.
Sattarnezhad, Neda
Diaz-Cruz, Camilo
Polgar-Turcsanyi, Mariann
Tummala, Subhash
Bakshi, Rohit
Bajaj, Vikram S.
Ben-Shimol, David
Bikhchandani, Nikhil
Blocker, Alexander W.
Burkart, Joshua
Cendrillon, Raphael
Cusack, Michael P.
Demiralp, Emre
Jooste, Sarel Kobus
Kharbouch, Alaa
Lee, Amy A.
Lehár, Joseph
Liu, Manway
Mahadevan, Swaminathan
Murphy, Mark
Norton, Linda C.
Parlikar, Tushar A.
Pathak, Anupam
Shoeb, Ali
Soderberg, Erin
Stephens, Philip
Stoertz, Aaron H.
Thng, Florence
Tumkur, Kashyap
Wang, Hongsheng
Rhodes, Jane
Rudick, Richard A.
Ransohoff, Richard M.
Phillips, Glenn A.
Bruzik, Effie
Marks, William J.
Weiner, Howard L.
Snyder, Thomas M.
author_sort Chitnis, Tanuja
collection PubMed
description Technological advances in passive digital phenotyping present the opportunity to quantify neurological diseases using new approaches that may complement clinical assessments. Here, we studied multiple sclerosis (MS) as a model neurological disease for investigating physiometric and environmental signals. The objective of this study was to assess the feasibility and correlation of wearable biosensors with traditional clinical measures of disability both in clinic and in free-living in MS patients. This is a single site observational cohort study conducted at an academic neurological center specializing in MS. A cohort of 25 MS patients with varying disability scores were recruited. Patients were monitored in clinic while wearing biosensors at nine body locations at three separate visits. Biosensor-derived features including aspects of gait (stance time, turn angle, mean turn velocity) and balance were collected, along with standardized disability scores assessed by a neurologist. Participants also wore up to three sensors on the wrist, ankle, and sternum for 8 weeks as they went about their daily lives. The primary outcomes were feasibility, adherence, as well as correlation of biosensor-derived metrics with traditional neurologist-assessed clinical measures of disability. We used machine-learning algorithms to extract multiple features of motion and dexterity and correlated these measures with more traditional measures of neurological disability, including the expanded disability status scale (EDSS) and the MS functional composite-4 (MSFC-4). In free-living, sleep measures were additionally collected. Twenty-three subjects completed the first two of three in-clinic study visits and the 8-week free-living biosensor period. Several biosensor-derived features significantly correlated with EDSS and MSFC-4 scores derived at visit two, including mobility stance time with MSFC-4 z-score (Spearman correlation −0.546; p = 0.0070), several aspects of turning including turn angle (0.437; p = 0.0372), and maximum angular velocity (0.653; p = 0.0007). Similar correlations were observed at subsequent clinic visits, and in the free-living setting. We also found other passively collected signals, including measures of sleep, that correlated with disease severity. These findings demonstrate the feasibility of applying passive biosensor measurement techniques to monitor disability in MS patients both in clinic and in the free-living setting.
format Online
Article
Text
id pubmed-6906296
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69062962019-12-13 Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis Chitnis, Tanuja Glanz, Bonnie I. Gonzalez, Cindy Healy, Brian C. Saraceno, Taylor J. Sattarnezhad, Neda Diaz-Cruz, Camilo Polgar-Turcsanyi, Mariann Tummala, Subhash Bakshi, Rohit Bajaj, Vikram S. Ben-Shimol, David Bikhchandani, Nikhil Blocker, Alexander W. Burkart, Joshua Cendrillon, Raphael Cusack, Michael P. Demiralp, Emre Jooste, Sarel Kobus Kharbouch, Alaa Lee, Amy A. Lehár, Joseph Liu, Manway Mahadevan, Swaminathan Murphy, Mark Norton, Linda C. Parlikar, Tushar A. Pathak, Anupam Shoeb, Ali Soderberg, Erin Stephens, Philip Stoertz, Aaron H. Thng, Florence Tumkur, Kashyap Wang, Hongsheng Rhodes, Jane Rudick, Richard A. Ransohoff, Richard M. Phillips, Glenn A. Bruzik, Effie Marks, William J. Weiner, Howard L. Snyder, Thomas M. NPJ Digit Med Article Technological advances in passive digital phenotyping present the opportunity to quantify neurological diseases using new approaches that may complement clinical assessments. Here, we studied multiple sclerosis (MS) as a model neurological disease for investigating physiometric and environmental signals. The objective of this study was to assess the feasibility and correlation of wearable biosensors with traditional clinical measures of disability both in clinic and in free-living in MS patients. This is a single site observational cohort study conducted at an academic neurological center specializing in MS. A cohort of 25 MS patients with varying disability scores were recruited. Patients were monitored in clinic while wearing biosensors at nine body locations at three separate visits. Biosensor-derived features including aspects of gait (stance time, turn angle, mean turn velocity) and balance were collected, along with standardized disability scores assessed by a neurologist. Participants also wore up to three sensors on the wrist, ankle, and sternum for 8 weeks as they went about their daily lives. The primary outcomes were feasibility, adherence, as well as correlation of biosensor-derived metrics with traditional neurologist-assessed clinical measures of disability. We used machine-learning algorithms to extract multiple features of motion and dexterity and correlated these measures with more traditional measures of neurological disability, including the expanded disability status scale (EDSS) and the MS functional composite-4 (MSFC-4). In free-living, sleep measures were additionally collected. Twenty-three subjects completed the first two of three in-clinic study visits and the 8-week free-living biosensor period. Several biosensor-derived features significantly correlated with EDSS and MSFC-4 scores derived at visit two, including mobility stance time with MSFC-4 z-score (Spearman correlation −0.546; p = 0.0070), several aspects of turning including turn angle (0.437; p = 0.0372), and maximum angular velocity (0.653; p = 0.0007). Similar correlations were observed at subsequent clinic visits, and in the free-living setting. We also found other passively collected signals, including measures of sleep, that correlated with disease severity. These findings demonstrate the feasibility of applying passive biosensor measurement techniques to monitor disability in MS patients both in clinic and in the free-living setting. Nature Publishing Group UK 2019-12-11 /pmc/articles/PMC6906296/ /pubmed/31840094 http://dx.doi.org/10.1038/s41746-019-0197-7 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Chitnis, Tanuja
Glanz, Bonnie I.
Gonzalez, Cindy
Healy, Brian C.
Saraceno, Taylor J.
Sattarnezhad, Neda
Diaz-Cruz, Camilo
Polgar-Turcsanyi, Mariann
Tummala, Subhash
Bakshi, Rohit
Bajaj, Vikram S.
Ben-Shimol, David
Bikhchandani, Nikhil
Blocker, Alexander W.
Burkart, Joshua
Cendrillon, Raphael
Cusack, Michael P.
Demiralp, Emre
Jooste, Sarel Kobus
Kharbouch, Alaa
Lee, Amy A.
Lehár, Joseph
Liu, Manway
Mahadevan, Swaminathan
Murphy, Mark
Norton, Linda C.
Parlikar, Tushar A.
Pathak, Anupam
Shoeb, Ali
Soderberg, Erin
Stephens, Philip
Stoertz, Aaron H.
Thng, Florence
Tumkur, Kashyap
Wang, Hongsheng
Rhodes, Jane
Rudick, Richard A.
Ransohoff, Richard M.
Phillips, Glenn A.
Bruzik, Effie
Marks, William J.
Weiner, Howard L.
Snyder, Thomas M.
Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
title Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
title_full Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
title_fullStr Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
title_full_unstemmed Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
title_short Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
title_sort quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906296/
https://www.ncbi.nlm.nih.gov/pubmed/31840094
http://dx.doi.org/10.1038/s41746-019-0197-7
work_keys_str_mv AT chitnistanuja quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT glanzbonniei quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT gonzalezcindy quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT healybrianc quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT saracenotaylorj quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT sattarnezhadneda quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT diazcruzcamilo quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT polgarturcsanyimariann quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT tummalasubhash quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT bakshirohit quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT bajajvikrams quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT benshimoldavid quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT bikhchandaninikhil quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT blockeralexanderw quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT burkartjoshua quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT cendrillonraphael quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT cusackmichaelp quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT demiralpemre quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT joostesarelkobus quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT kharbouchalaa quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT leeamya quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT leharjoseph quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT liumanway quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT mahadevanswaminathan quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT murphymark quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT nortonlindac quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT parlikartushara quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT pathakanupam quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT shoebali quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT soderbergerin quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT stephensphilip quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT stoertzaaronh quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT thngflorence quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT tumkurkashyap quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT wanghongsheng quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT rhodesjane quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT rudickricharda quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT ransohoffrichardm quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT phillipsglenna quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT bruzikeffie quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT markswilliamj quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT weinerhowardl quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis
AT snyderthomasm quantifyingneurologicdiseaseusingbiosensormeasurementsinclinicandinfreelivingsettingsinmultiplesclerosis